Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 305

1.

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.

Chorba JS, Galvan AM, Shokat KM.

J Vis Exp. 2018 Aug 28;(138). doi: 10.3791/58265.

PMID:
30222160
2.

Chemical genetic inhibition of DEAD-box proteins using covalent complementarity.

Barkovich KJ, Moore MK, Hu Q, Shokat KM.

Nucleic Acids Res. 2018 Aug 8. doi: 10.1093/nar/gky706. [Epub ahead of print]

PMID:
30102385
3.

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.

Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S.

Nat Chem Biol. 2018 Aug;14(8):768-777. doi: 10.1038/s41589-018-0081-9. Epub 2018 Jun 25.

PMID:
29942081
4.

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.

Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP.

PLoS One. 2018 May 25;13(5):e0193849. doi: 10.1371/journal.pone.0193849. eCollection 2018.

5.

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Chorba JS, Galvan AM, Shokat KM.

J Biol Chem. 2018 May 4;293(18):6692. doi: 10.1074/jbc.AAC118.003335. No abstract available.

6.

Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP.

Hu Q, Shokat KM.

Cell. 2018 May 17;173(5):1254-1264.e11. doi: 10.1016/j.cell.2018.03.018. Epub 2018 Apr 5.

PMID:
29628140
7.

Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.

Nnadi CI, Jenkins ML, Gentile DR, Bateman LA, Zaidman D, Balius TE, Nomura DK, Burke JE, Shokat KM, London N.

J Chem Inf Model. 2018 Feb 26;58(2):464-471. doi: 10.1021/acs.jcim.7b00399. Epub 2018 Jan 31.

PMID:
29320178
8.

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Chorba JS, Galvan AM, Shokat KM.

J Biol Chem. 2018 Feb 9;293(6):1875-1886. doi: 10.1074/jbc.RA117.000754. Epub 2017 Dec 19. Erratum in: J Biol Chem. 2018 May 4;293(18):6692.

PMID:
29259136
9.

Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.

Gentile DR, Rathinaswamy MK, Jenkins ML, Moss SM, Siempelkamp BD, Renslo AR, Burke JE, Shokat KM.

Cell Chem Biol. 2017 Dec 21;24(12):1455-1466.e14. doi: 10.1016/j.chembiol.2017.08.025. Epub 2017 Oct 12.

PMID:
29033317
10.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD.

J Med Chem. 2017 Dec 28;60(24):9976-9989. doi: 10.1021/acs.jmedchem.7b01192. Epub 2017 Oct 9.

PMID:
28933846
11.

A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice.

Morisot N, Novotny CJ, Shokat KM, Ron D.

Addict Biol. 2018 Mar;23(2):713-722. doi: 10.1111/adb.12528. Epub 2017 Jul 6.

PMID:
28681511
12.

Drugging the 'undruggable' cancer targets.

Dang CV, Reddy EP, Shokat KM, Soucek L.

Nat Rev Cancer. 2017 Aug;17(8):502-508. doi: 10.1038/nrc.2017.36. Epub 2017 Jun 23. Review.

13.

Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes.

McGregor LM, Jenkins ML, Kerwin C, Burke JE, Shokat KM.

Biochemistry. 2017 Jun 27;56(25):3178-3183. doi: 10.1021/acs.biochem.7b00271. Epub 2017 Jun 16.

14.

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.

Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML.

Sci Transl Med. 2017 Jun 14;9(394). pii: eaah6144. doi: 10.1126/scitranslmed.aah6144.

15.

Site-specific incorporation of phosphotyrosine using an expanded genetic code.

Hoppmann C, Wong A, Yang B, Li S, Hunter T, Shokat KM, Wang L.

Nat Chem Biol. 2017 Aug;13(8):842-844. doi: 10.1038/nchembio.2406. Epub 2017 Jun 12.

16.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

17.

Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.

Novotny CJ, Hamilton GL, McCormick F, Shokat KM.

ACS Chem Biol. 2017 Jul 21;12(7):1956-1962. doi: 10.1021/acschembio.7b00374. Epub 2017 Jun 19.

18.

Long-term oral kinetin does not protect against α-synuclein-induced neurodegeneration in rodent models of Parkinson's disease.

Orr AL, Rutaganira FU, de Roulet D, Huang EJ, Hertz NT, Shokat KM, Nakamura K.

Neurochem Int. 2017 Oct;109:106-116. doi: 10.1016/j.neuint.2017.04.006. Epub 2017 Apr 20.

PMID:
28434973
19.

A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, Truong AY, Cayanan G, Simonds EF, Haas-Kogan D, Phillips JJ, Nicolaides T, Okaniwa M, Shokat KM, Weiss WA.

Cancer Cell. 2017 Mar 13;31(3):424-435. doi: 10.1016/j.ccell.2017.01.014.

20.

INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.

Reed DE, Shokat KM.

Mol Cancer Res. 2017 Jun;15(6):765-775. doi: 10.1158/1541-7786.MCR-16-0183. Epub 2017 Feb 14.

Supplemental Content

Loading ...
Support Center